Tacrolimus/MMF Regimen Cuts Acute Rejection Rate

Share this content:

In a long-term randomized trial of 150 kidney transplant recipients with a median follow-up of eight years post-transplant, those undergoing immunosuppressive therapy with tacrolimus/mycophenolate mofetil (MMF) experienced significantly less frequent acute rejection (12%) than those treated with tacrolimus/sirolimus (30%) or cyclosporine/sirolimus (28%), according to a report in the Journal of the American Society of Nephrology (2011;22:1758-1768).

In addition, the rate of dying with a functioning graft was significantly higher among those receiving tacrolimus/sirolimus (26%) than among the patients who received tacrolimus/MMF (12%) or cyclosporine/sirolimus (4%).

The researchers observed no significant differences in actuarial graft survival eight years post-transplant among the groups. Of 29 observed graft failures, patient noncompliance appeared to be responsible for 13 (45%), with 11 of these occurring after 36 months.

You must be a registered member of Renal and Urology News to post a comment.